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Abstract Many studies have focused on the behavior and
cognitive problems in young patients with fragile X syndrome
(FXS), but there are no studies about the problems in aging for
those with FXS. The discovery of the fragile X-associated
tremor ataxia syndrome (FXTAS), a neurodegenerative disor-
der related to elevated FMR1-mRNA, in elderly men and
some women with the premutation, intensified the need for
aging studies in FXS. Approximately 40% of males with FXS
have repeat size mosaicism and as a result, some of these
individuals also have elevated levels of FMR1-mRNA which
theoretically puts them at risk for FXTAS. Here, we have
surveyed all of the aging patients with FXS that we have
followed over the years to clarify the medical complications
of aging seen in those with FXS. Data was collected from 62
individuals with the FXS full mutation (44 males; 18 females)
who were at least 40 years old at their most recent clinical
examination. We found that the five most frequent medical
problems in these patients were neurological problems
(38.7%), gastrointestinal problems (30.6%), obesity (28.8%),
hypertension (24.2%) and heart problems (24.2%). Movement
disorders were significantly different between males and
females (38.6% vs.10.2%, p=0.029). We did not find any
differences in medical problems between those with a full
mutation and those with mosaicism. Identification of medical
problems associated with aging in FXS is important to
establish appropriate recommendations for medical screening
and treatment considerations.
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Fragile X syndrome (FXS) is the most common heritable
form of intellectual disability (ID) known. Characteristic
physical features include large and prominent ears, long
narrow face, macroorchidism, high-arched palate, hyper-
extensible finger joints, double-jointed thumbs, single
palmar crease, flat feet often with pronation and hand
calluses. FXS causes a variety of learning, emotional and
behavior problems including autism (Hagerman 2002;
Chonchaiya et al. 2009). The prevalence of the full
mutation was estimated to be 1 in ∼3600 males (Crawford
et al. 2002), although the allele frequency was found to be 1
in 2633 in newborn screening in Spain (Fernandez-Carvajal
et al. 2009).
FXS is caused by a CGG repeat expansion located in 5′
untranslated region of the fragile X mental retardation 1
(FMR1) gene. Normally the repeat size is 5–44 CGG
repeats, while premutation alleles have 55–200 repeats and
full mutation alleles have more than 200 CGG repeats. With
expansion beyond 200 repeats, the surrounding promoter
region of the FMR1 gene is hypermethylated, inhibiting
FMR1 transcription and resulting in absence or reduction of
the protein product, fragile X mental retardation protein
(FMRP) (Oostra and Willemsen 2009). As a result of X-
linkage, affected males have a more severe phenotype than
affected females, in whom phenotype is modulated by the
activation ratio of the normal X chromosome. The variation
in the clinical phenotype is also related to variability of the
mutation, such as lack of methylation and size mosaicism
leading to higher levels of FMRP than are observed in
individuals with only a fully methylated full mutation
(Jin and Warren 2000; Loesch et al. 2004).
Many studies have focused on the behavior and
cognitive problems in young patients with FXS. There
are no studies about the problems in aging of those with
FXS. There are a few reports of declining IQ as patients
progress through childhood and into adulthood (Wright-
Talamante et al. 1996; Lachiewicz et al. 1987) and one
case of a neurodegenerative course in FXS thought to be
due to an additional diagnosis of amyotrophic lateral
sclerosis (ALS) (Desai et al. 1990). There have also been
reports of rare sudden death in FXS in adulthood and these
are presumed to be related to cardiac arrhythmias
exacerbated by mitral valve prolapse which is common
in adults with FXS (Hagerman 2002). A neuropathological
study of 2 older males with FXS demonstrated loss of
Purkinje cells and Bergman gliosis in the cerebellum in
one of the cases (Sabaratnam 2000). Our neuropatholog-
ical studies in three cases of older males with FXS have
also demonstrated Purkinje cell loss in the cerebellum
suggesting a more pronounced affect of aging in those
with FXS compared to age matched controls without FXS
(Greco et al. 2009). The discovery of the fragile X-
associated tremor ataxia syndrome (FXTAS) (Hagerman et
al. 2001; Berry-Kravis et al. 2007) in elderly men and
some women (Coffey et al. 2008) with the premutation
intensified the need for more detailed aging studies in
FXS. FXTAS is a neurodegenerative disorder caused by
elevated FMR1-mRNA. Persons with FXS would not be
expected to be at risk for FXTAS, since generally they do
not usually produce FMR1 mRNA. However, approxi-
mately 40% of males with FXS have repeat size
mosaicism (Nolin et al. 1994) and some of these
individuals also have elevated levels of FMR1-mRNA
(Allen et al. 2004; Tassone et al. 2001). The latter would
theoretically be at risk for FXTAS. Although FXTAS has
never been reported in a person with FXS (Harris et al.
2008), some families are concerned about cognitive
decline in their older members with FXS. These concerns
have been intensified because of the recent report that
FMRP regulates the translation of amyloid precursor
protein (APP), such that the absence of FMRP leads to
up-regulation of APP (Westmark and Malter 2007). Thus
persons with FXS and absent or diminished FMRP may be
at greater risk for Alzheimers Disease (AD).
The behavior problems in FXS include mood instability
and aggression in approximately 75% (Hessl et al. 2008),
often resulting in treatment with atypical antipsychotic
medication (Hagerman et al. 2009). Prolonged use of
antipsychotics in FXS puts individuals at risk for
antipsychotic-induced movement disorders including tar-
dive dyskinesia and parkinsonism (Caligiuri et al. 2009;
Orti-Pareja et al. 1999; Miller et al. 2005) that can reduce
the quality of life in elderly patients. In addition, the
dysregulation of dopamine function in the absence of
FMRP (Wang et al. 2008) also may put those with FXS at
risk for Parkinson’s Disease (PD). Although patients with
FXS have not previously been reported to have PD or a loss
of dopamine in the substancia nigra, there is a dysregulation
of dopamine in the neurons in hippocampal slice prepara-
tions that can be normalized by adding FMRP or by adding
a stimulant medication (Wang et al. 2008).
In this study, we have surveyed all of the aging patients
with FXS that we have followed over the years (from 1991
to 2009) to begin to clarify the medical complications of
individuals with FXS over 40.
Methods
This is a retrospective uncontrolled study of a conve-
nience sample (patients were either clinically referred
for an evaluation of FXS or seen as part of a research
protocol). Data was collected from 62 individuals with
the FXS full mutation who were at least 40 years old at
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included 62 patients (44 males and 18 females), ranging
from 40–71 years of age, with mean age of 49.7±
8.0 year. Data was identified from clinical and research
evaluations of subjects with FXS at one of three sites
spanning from 1991 to 2009. Patients and their families
consented to use of medical data under specifications of
each institution’s research review board. Patients were
seen at the University of California, Davis, Medical Investi-
gation of Neurodevelopmental Disorders (M.I.N.D) Institute
(n=23), University of Colorado, Denver (n=24), and
Rush University Medical Center, Chicago (n=15). A
common medical history and examination data form
was used at all of the centers. This form had been
implemented for data collection in previous collabora-
tions and an earliar version of this data sheet was used
to collect information for past reports (Riddle et al.
1998).
Full scale IQ, comprehensive medical history, phys-
ical characteristics, and current and past medication use
were collected from medical records. The number of
CGG repeats, percentage of methylation, and percentage
of FMRP and mRNA were measured, if samples were
available. BMI (weight (kg)/height (m)2 was used to
assess obesity; BMI cutoff criteria for overweight and
o b e s ew e r e2 5-< 3 0a n d≥3 0 ,r e s p e c t i v e l y( O g d e ne ta l .
2006).
Descriptive analyses were done to determine the char-
acteristics of the subjects. The statistical method used was
the Fisher Exact Test to compare the medical problems
between male and female patients and also between full
mutation and mosaic individuals.
Results
Characteristic of the subjects
The mean age in males 50.2±8 y and females 48.5±
7.8 y were not significantly different (p=0.451). There
was no significant differences (p=0.752) between mean
age of the patients with full mutation alleles (49.6±
7.4 year) compared with patients with mosaic alleles (50.4
±10.3 year). Of 52 patients for whom measurement of
Body Mass Index (BMI) was available, the mean of the
BMI was 28.5±5 (28.8% obese and 53.8% overweight).
The molecular studies of 60 patients showed that 46
patients (76.7%) had a hypermethylated full mutation
whereas 14 (23.3.%) were mosaic patients (either size or
methylation mosaicism ). Two (3.2%) patients were DNA
positive for fragile X (>200 repeats) but their exact CGG
repeat number was unavailable. Five of 18 (27.8%)
females and 9 of 44 (20.5%) males were mosaics. There
was no significant difference between males and females in
the percentage with a full mutation or mosaicism (p=0.412).
The full scale IQ was assessed by the Wechsler Adult
Intelligence Scale-Third Edition (WAIS-III) , Wechsler
Adult Intelligence Scale - Revised (WAIS-R), Wechsler
Abbreviated Scale of Intelligence (WASI), or Stanford
Binet from 44 patients who completed this testing
ranged from 36 to 122 with a mean of 58±19. The
mean IQ was significally higher in the group of female
patients (77±17.4) than in the male patients (51.5±14.3,
p<0.001). Of 43 patients who have IQ data and DNA
category available, the IQ of those with mosaicism (69.2±
18.6) was significantly higher than those with the full
mutation only (55.4±18 ; p=0.036).
Medical problems
We found that the five most frequent medical problems
in patients with FXS ≥ 40 years of age were
neurological problems (38.7%), gastrointestinal problems
(30.6%), obesity (28.8%), hypertension (24.2%) and
heart problems including mitral valve prolapse (MVP),
cardiac conduction abnormalities, heart attack, and heart
rhythm disorder (24.2%) (see Table 1). Males had a
significantly higher percentage of neurological problems
compared with females (47.7% vs 16.7%, p=0.021).
However, only movement disorders were significantly
different between males (38.6%) and females (10.2%,
p=0.029). The symptoms/diagnoses that were included in
movement disorders are tremor (9 patients, 14.5%),
Parkinson’s Disease (PD) (4 patients, 6.5%), bradykinesia
without PD (5 patients, 8.1%), tardive dyskinesia
(4 patients, 6.5%), and tics (3 patients, 4.8%). There were
12 patients with a history of seizures and the onset of
seizures was in adulthood for 5 (8.1%) patients (3 patients
had seizures at over 40 years of age).
Overall, of 52 patients who had BMI measurements, 43
(82.6%) were in the obese (28.8%) or overweight (53.8%)
category. The mean BMI in females (32±5.4) was
significantly higher (p<0.001) than that of males (26.9±
3.9). Accordingly, significantly less males (13.9%) than
females (62.5%; p=0.001) were obese. However, more
males (63.9%) met criteria for being overweight than
females (31.2%). There were no significant differences in
medical problems between those with a full mutation as
compared to those with mosaicism.
Medication
Table2 shows the current medications of the subjects. Almost
half of the patients were taking psychopharmacologic
medication including selective serotonin reuptake inhibitors
(SSRIs), serotonin and norepinephrine reuptake inhibitors
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(thioridazine) and other medication (benzodiazepines, bupro-
pion, buspirone).
Discussion
This is the only study to date to describe the medical
problems in patients with FXS 40 years and older. The
neurodegeneration seen in aging premutation carriers with
FXTAS is thought to be secondary to the elevated level of
FMR1 mRNA which usually does not occur in those with
FXS. However, rarely elevated FMR1 mRNA can be seen
in those with the full mutation and a high level of
mosaicism, although this has not been associated with
neurodegeneration or autism (Harris et al. 2008; Tassone et
al. 2001, 2000). In this review of 62 patients, we did not
identify any patients with FXS who have FXTAS. However,
we did find significant neurological problems with aging,
more so in males than females, including PD and movement
disorders. While overall the presence of neurological prob-
lems was not related to the molecular status (mosaicism) of
the patient, we found PD in four of 44 males (9.1%), and the
one with earliest onset at age 42, had mosaicism with the
highest mRNA level (10.29±0.78). There were 3 of 12
males (20%) over age 55 with PD compared to the expected
rate of 1.2% of males with PD seen in the general population
55 years old and older (de Rijk et al. 1995). A larger study of
aging patients with FXS is needed to understand whether the
rate of PD is higher in FXS compared to the general
population as found in this study. All of the patients with PD
and FXS had been treated for many years with antipsy-
chotics, although usually atypical antipsychotics have been
used since they became available in the 1990s. The atypical
antipsychotics have a lower incidence of movement disorder
sequelae, particularly tartive dyskinesias, than first genera-
tion antipsychotics, although even these newer drugs can be
associated with symptoms of PD (Cortese et al. 2008). It is
Table 1 The number and percentage of medical problems in patients with FXS ≥ 40 years
Problems Sex
a DNA Status
b Total subjects
(n=62)
n Male
(n=44)
Female
(n=18)
pn Full mutation
( n=46)
Mosaic
(n=14)
p
All neurological problems 62 21 (47.7%) 3(16.7%) 0.021* 60 19(41.3%) 3(21.4%) 0.150 24(38.7%)
Movement disorder 62 17(38.6%) 2(10.2%) 0.029* 60 14(30.4%) 3(21.4%) 0.386 19(30.6%)
• Tremor 62 8(18.2%) 1(5.6%) 0.192 60 7(15.2%) 2(14.3%) 0.651 9(14.5%)
• Ataxia 62 6(13.6%) 1(5.6%) 0.336 60 4(8.7%) 3(21.4%) 0.199 7(11.3%)
• Parkinsonism 62 4(9.1%) 0 0.243 60 2(4.3%) 2(14.3%) 0.230 4(6.5%)
• Tardive dyskinesia 62 4(9.1%) 0 0.243 60 1(2.2%) 1(7.1%) 0.415 4(6.5%)
• Bradykinesia without PD 62 5(11.4%) 0 0.168 60 5(10.9%) 0 0.251 5(8.1%)
• Tics 62 2(4.5%) 1(5.6%) 0.650 60 3(6.5%) 0 0.444 3(4.8%)
Seizure 62 10(22.7%) 2 (11.1%) 0.249 60 10(21.7%) 1(7.1%) 0.205 12(19.4%)
Multiple Sclerosis 62 1(2.3%) 0 0.710 60 0 0 1(1.6%)
Gastrointestinal Problem 62 14(31.8%) 5(27.8%) 0.503 60 13(28.3%) 4(28.6%) 0.614 19(30.6%)
Obesity 52
# 5(13.9%) 10(62.5%) 0.001* 51
$ 12(30.0%) 3(27.3%) 0.589 15(28.8%)
Hypertension 62 9(20.5%) 6(33.3%) 0.224 60 12 (26.1%) 2(14.3%) 0.300 15(24.2%)
Heart problem 62 13(29.5%) 2(11.1%) 0.110 60 12 (26.1%) 2(14.3%) 0.300 15(24.2%)
History of Decline 62 10(22.7%) 4(22.2%) 0.437 60 9(19.6%) 3(21.4%) 0.574 14(22.6%)
Autonomic problem 62 9(20.5%) 2(11.1%) 0.316 60 7(15.2%) 3(21.4%) 0.426 11(17.7%)
Memory problem 62 9(20.5%) 2(11.1%) 0.316 60 8(17.4%) 3(21.4%) 0.502 11(17.7)
Dementia/cognitive decline 62 4(9.1%) 2(11.1%) 0.567 60 4(8.7%) 1(7.1%) 0.669 6 (9.7%)
Kidney Problem 62 5(11.4%) 2(11.1%) 0.674 60 6(13.0%) 1(7.1%) 0.478 7(11.3%)
Respiratory Problem 62 4(9.1%) 2(11.1%) 0.567 60 4(8.7%) 1(7.1%) 0.669 6(9.7%)
Swallowing Problem 62 4(9.1%) 0 0.243 60 2 (4.3%) 1(7.1%) 0.556 4(6.5%)
Diabetes 62 3(6.8%) 1(5.6%) 0.671 60 3(6.5%) 1(7.1%) 0.665 4(6.5%)
Thyroid problems 62 3(6.8%) 1(5.6%) 0.671 60 3(6.5%) 1(7.1)0 0.665 4(6.5%)
Cancer 62 2 (4.5%) 0 0.500 60 0 1(7.15) 0.233 2(3.2%)
• Percentage within sex
a and DNA status
b
• # n=52, male=36, female=16 ; $ n=51, full=40, mosaic=11
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reported here relates to this treatment. These patients were
taken off neuroleptics when PD symptoms started but their
PD progressed. In one patient lowering the dose of the
atypical antipsychotic seemed to decrease the symptoms of
PD and in others the symptoms of motor dysfunction
improved with lowering the dose of atypicals also. However,
it is also possible that the PD-like symptoms such as tremor
or balance problems seen in FXS are exacerbated by the loss
of Purkinje cells and resultant cerebellar compromise. There
is also cellular evidence for significant dysfunction of the
dopamine system in FXS related to the lack of FMRP (Wang
et al. 2008), although the substantia nigra has not been
directly studied in FXS. In those patients with PD and FXS
there was cognitive decline and this can occur in PD in
general (Muslimovic et al. 2009).
The prevalence of obesity has increased in the US
population over the last decade so it is not unexpected to
see significant rates of obesity in those with FXS in the
current study. The obesity epidemic in the US is related to
the lack of physical activity (Brock DW, 2009) and our diet
composition (Murtaugh MA, 2007). Additionally, in those
with FXS the tendency for more reclusive behavior with
age (Hatton et al. 2006), the use of atypicals that increase
the appetite and the presence of the Prader-Willi phenotype
(seen in less than 10% of patients with FXS) leading to
hyperphagia (Nowicki et al. 2007) may exacerbate the
obesity problem. In this study, 82.6% of patients with FXS
have either obesity (28.8%) or they are overweight (53.8%).
The percentage of obesity in these patients is slightly lower
than in the general population (34%) but the overweight
percentage is much higher than estimated in the general
population (33%) (Khan et al. 2009).
Hypertension is common in men with FXS, but the
prevalence has never been studied in detail (Hagerman
2002). Recently, the prevalence rate of hypertension in the
US general population was reported as 28.9% overall
(Cutler et al. 2008). Hypertension may be underrecognized
by the physician because anxiety and tactile defensiveness
in the clinical setting often leads to increased BP in patients
with FXS. Thus, a high value is often interpreted with
consideration of the stress and anxiety associated with the
medical visit. In this study 24% were diagnosed with
hypertension, and although this is not significantly different
from the general population it may be an underestimate of
the true incidence of this problem in FXS. Hypertension
may be more likely in individuals with FXS because of the
sympathetic hyperarousal documented in this syndrome
(Miller et al. 1999) and possibly because of elastin
abnormalities in the vessel walls as was documented in
one patient with FXS (Waldstein and Hagerman 1988). A
recent neuropathology study of three older men with FXS
who died (they are included in this study) showed
significant evidence of hyaloid changes in the blood vessels
presumed to be secondary to hypertensive disease. (Greco
et al. 2009). These results emphasize the need to diagnose
hypertension in those with FXS and treat it appropriately.
Kidney problems have been previously considered rare
in patients with FXS. We found 7 (11.3%) patients have
kidney problems including acute renal failure (2 patients),
urinary tract infection (2 patients), kidney stones (1 patient),
small cysts (1 patient), and 1 patient with a kidney problem
but unclear diagnosis. Connective tissue dysplasia, docu-
mented to be related to elastin abnormalities (Waldstein et
al. 1986) in FXS may lead to reflux and ureteral dilation
leading to renal failure and nephrectomy in one previous
case (Hagerman 2002). In this study, one patient had severe
prostate enlargement which lead to obstruction and renal
failure and this was relieved by surgery.
Two male patients were diagnosed with cancer including
one with an adenocarcinoma of the testicle and the other
with a malignant liver cancer that did not have a
pathological diagnosis. Some studies suggest a decreased
risk of cancer in individuals with FXS (Schultz-Pedersen et
al. 2001; Sund et al. 2009) perhaps related to PTEN down
regulation. However, there is also upregulation of the
mTOR pathway in FXS (Hoeffer et al. 2009) which can
lead to an increased risk of cancer (Matsumoto et al. 2009).
Medical Class Number and percentage
All medication 47 (75.8%)
Psychopharmacologic medication 29 (46.8%)
• SSRI/ SNRI 20 (68.9%)
$
• Atypical neuroleptic 13 (44.8%)
$
• Stimulant 0
• Other including benzodiazepines,
bupropion, buspirone, thioridazine
12(41.4%)
$
Anticonvulsants/mood stabilizer 8 (12.9%)
HBP and other CV medications 18 (29%)
Gastrointestinal medications 9 (14.5%)
Table 2 Current medication
documented in study patients
(n=62)
$Percentage represents the % of
those who took psychopharmaco-
logical medications;HBP high
blood pressure; CV cardiovascular
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15–20% and they are usually well controlled with anti-
convulsants (Berry-Kravis 2002). However, our study found
that 8.1% of the patients had seizures that began in adulthood
with 3 patients developing seizures after age 40. Further
studies of seizures in aging are needed to assess whether
seizures in FXS tend to be a complication of aging and
whether a second peak of seizure onset (in addition to that
described in childhood) occurs late in life in FXS (Hagerman
and Stafstorm 2009). Clinicians should be alert to the
possibility of seizures in adult and aging patients with FXS.
An additional notable finding in our study is the lack of
significant atherosclerotic heart disease or late onset
complications of mitral valve prolapse which is thought to
be present in over 50% of adult males with FXS (Hagerman
2002).
The limitations of this study include lack of typical or
intellectually impaired controls, intellectually impaired
subjects, cohort effects due to the small sample size,
retrospective chart review and referral bias to well-known
FXS clinics. However, this study is a first step toward
understanding the medical problems associated with aging
in those with FXS.
In summary, we have found a number of medical
problems associated with aging in individuals with FXS
that may be related to the neurobiological changes in this
disorder. Of most concern is the higher incidence of PD and
other movement disorders. Since these may be related to
long term use of atypical antipsychotics, the risks and
benefits for continued use should be weighed in aging
individuals with FXS. All of the atypical antipsychotics can
be associated with parkinsonism except quetiapine (sero-
quel), which is frequently used for managing hallucinations
in the PD population because of it’s minimal motor side
effects (Cortese et al. 2008). In addition, vigorous identi-
fication and treatment of hypertension is warranted because
of the CNS effects of untreated hypertension.
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